Financial Brief: Eli Lilly Exceeds 2026 Revenue and Earnings Guidance, Boosted by Weight Loss Drug Demand - LLY

[Para 1: The Lead] Eli Lilly (LLY-US) has surpassed its 2026 revenue and earnings guidance, driven by robust demand for its weight loss and diabetes medications. The company projects a 2026 revenue range of $80 billion to $83 billion, exceeding market expectations of approximately $77.6 billion. Adjusted earnings per share (EPS) are forecast between $33.50 and $35, outpacing analyst estimates. Shares of LLY rose 7.50% to $1,078.73 in pre-market trading. [Para 2-3: Supporting details & Context] Lilly attributes its strong performance to the continued surge in demand for its weight loss drug Mounjaro and diabetes treatment Zepbound. The company anticipates that Medicare's expanded coverage of weight loss drugs will further expand the obesity medication market this year. Lilly is also awaiting the FDA's decision on its oral weight loss drug orforglipron, which could be announced as early as April. The company has ramped up production capacity in anticipation of potential approval. In a broader context, the weight loss drug market faces increased pricing pressures. Competitor Novo Nordisk (NVO-US) warned of unprecedented price pressure in the U.S. market, forecasting a significant decline in revenue this year. In contrast, market analysts believe Lilly is better positioned due to its patent protection and product portfolio. Its core products Mounjaro and Zepbound have approximately ten years of patent protection, and Lilly has been proactive in addressing generic drug and low-cost alternatives, mitigating short-term impacts. Lilly's financial report for the fourth quarter of the 2025 fiscal year (ending December 31, 2025) showed revenue of $19.3 billion, surpassing market expectations of approximately $18 billion. Earnings per share were $7.54, exceeding analyst estimates. Sales of Zepbound for the quarter reached $4.3 billion, significantly exceeding market expectations. Meanwhile, Mounjaro sales reached $7.4 billion, with international market growth continuing to expand.